The Georgia Research Alliance (GRA) awarded a Phase 2A grant of $53,334 to Dr. Hans Grossniklaus for studies that test OncoSpherix’s lead clinical candidate, the dual HIF inhibitor 64B, as part of combination therapy with tyrosine kinase inhibitors in mouse models of uveal melanoma. Funds are also being used to support some route scouting for the synthesis of 64B. “We appreciate the grant from GRA that supports studies at Emory on the compounds that OncoSpherix has licensed”, stated Margaret K. Offermann, President and CEO of OncoSpherix. GRA is a nonprofit (501c3), public-private partnership that partners with both the University System of Georgia and Georgia’s Department of Economic Development. GRA’s venture development program seeds companies with investment at an early-stage and also provides spin-out companies with executive guidance.
